<DOC>
	<DOCNO>NCT00002735</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining one chemotherapy drug radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy radiation therapy treat patient stage III stage IV cancer hypopharynx tongue .</brief_summary>
	<brief_title>SWOG-9451 , Combination Chemo &amp; RT For Patients With Stage III/Stage IV Cancer Hypopharynx Tongue</brief_title>
	<detailed_description>OBJECTIVES : I . Determine complete histologic response rate ( represent rate organ preservation ) induction cisplatin/fluorouracil follow radiotherapy plus cisplatin patient select stage III/IV cancer hypopharynx base tongue . II . Evaluate feasibility accrue treat patient regimen multi-institutional setting . III . Determine overall complete response rate patient . OUTLINE : This multicenter study . Patients stratify accord center tumor site ( hypopharynx v base tongue ) . Base tongue stratum close November 15 , 1998 . Regimen A : Patients receive cisplatin IV 90 minute day 1 22 fluorouracil IV 120 minute day 1-5 22-26 . Patients measurable neck node discontinue therapy disease progress day 22 . All patient achieve complete partial response day 43 proceed regimen B . All others proceed resection follow radiotherapy ( study ) . Regimen B ( begin within 3-4 week start second induction course ) : Patients receive cisplatin IV 90 minute every 3 week 3 course . Concurrently , patient receive radiotherapy 5 day week 5.6 week . Patients reassess 8-12 week radiotherapy . Patients disease free observe . Other patient undergo surgical resection node and/or primary tumor . Patients follow every 4-6 week 1 year , every 2 month 1 year , every 4 month 2 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : Up 70 patient ( 35/tumor site ) accrue study 3.5 year .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma hypopharynx base tongue newly diagnose consider resectable For hypopharyngeal cancer , total laryngectomy would require surgery Disease stag clinical exam , endoscopy , CT MRI Stage III T23 N01 M0 Stage IV T23 N23 M0 Measurable evaluable disease pleural effusion , ascites , disease document indirect evidence Closed patient cancer base tongue 11/15/1998 PATIENT CHARACTERISTICS : Age : Adult Performance status : SWOG 0 1 Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 time normal AST ALT great 3 time normal Renal : Creatinine great 2 time normal Creatinine clearance least 60 mL/min Magnesium normal ( supplementation allow ) Other : Average hearing loss ear great 40 dB 502,000 Hz range No second malignancy within 5 year except : Adequately treat nonmelanomatous skin cancer Carcinoma situ cervix Stage I/II cancer ( head/neck ) complete remission Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : No prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
</DOC>